proxyvotesnow.com

Home › Companies › Ironwood Pharmaceuticals, Inc. › 2025-2026

Ironwood Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Ironwood Pharmaceuticals, Inc.’s Form 8-K, filed 2026-06-18 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 12Reported items
  • 196Asset managers
  • 2,418Fund votes
  • 2026-06-16Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Ironwood Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Ironwood Pharmaceuticals, Inc.

These tallies are Ironwood Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-18 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Ironwood Pharmaceuticals, Inc. — official shareholder meeting results, meeting held 2026-06-16
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Mark Currie, Ph.D. 107,222,711---- 2,414,99315,446,984 Majority: yes
Elect Director: Alexander Denner, Ph.D. 104,323,731---- 5,313,97315,446,984 Majority: yes
Elect Director: Jon Duane 105,956,515---- 3,681,18915,446,984 Majority: yes
Elect Director: Marla Kessler 107,142,336---- 2,495,36815,446,984 Majority: yes
Elect Director: Thomas McCourt 107,152,086---- 2,485,61815,446,984 Majority: yes
Elect Director: Julie McHugh 104,403,033---- 5,234,67115,446,984 Majority: yes
Elect Director: Catherine Moukheibir 106,410,985---- 3,226,71915,446,984 Majority: yes
Elect Director: Jay Shepard 107,209,046---- 2,428,65815,446,984 Majority: yes
Proposal 2: The stockholders approved, on a non-binding advisory basis, the compensation paid to the Company's named executive officers, as disclosed in the Proxy Statement for the Annual Meeting, based on the following votes: 104,461,9364,958,394217,374 --15,446,984 Majority: yes
Proposal 3: The stockholders approved the Plan Amendment, based on the following votes: 104,066,7855,404,112166,807 --15,446,984 Majority: yes
Proposal 4: The stockholders ratified the selection of KPMG LLP as the Company's independent registered public accounting firm for 2026, based on the following votes: 121,957,8952,783,154343,639 ---- Majority: yes

Source: Ironwood Pharmaceuticals, Inc., Form 8-K, filed with the SEC on 2026-06-18 — read the filing on EDGAR.

How asset managers voted at the Ironwood Pharmaceuticals, Inc. 2025-2026 meeting

Each item below shows how the 196 asset managers that disclosed a Ironwood Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Ironwood Pharmaceuticals, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Approval, by non-binding advisory vote, of the compensation paid to the named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 104,461,936AGAINST: 4,958,394

Ironwood Pharmaceuticals, Inc.’s own tally for this item (“Proposal 2: The stockholders approved, on a non-binding advisory basis, the compensation paid to the Company's named executive officers, as disclosed in the Proxy Statement for the Annual Meeting, based on the following ”): 104,461,936 for, 4,958,394 against, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 164,613,406 outstanding shares: 63% for, 3% against (66% of the company cast a for/against vote).

The 196 asset managers below cast 99% of the shares they voted on this item FOR (107,783,917 for, 1,265,762 against).

FOR 99%
FOR: 107,783,917 (98.8%)AGAINST: 1,265,762 (1.2%)ABSTAIN: 16,793 (0.0%)NOT VOTED: 2,344 (0.0%)
Largest asset managers voting on “Approval, by non-binding advisory vote, of the compensation paid to the named executive officers.” at Ironwood Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard13,933,20515 00For
BlackRock9,541,5060 00For
Charles Schwab9,512,3890 00For
State Street7,398,9720 00For
Fidelity5,789,3430 00For
AQR5,542,9420 00For
Federated Hermes5,538,6480 00For
Renaissance5,510,6980 00For
GEODE CAPITAL MANAGEMENT, LLC4,574,1160 00For
ACADIAN ASSET MANAGEMENT LLC4,382,7330 00For
Sarissa Capital Management LP3,485,5830 00For
MARSHALL WACE, LLP2,577,5400 00For
JACOBS LEVY EQUITY MANAGEMENT, INC2,499,1460 00For
Two Sigma2,491,2220 00For
SEI1,701,1280 00For
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP1,281,4220 00For
Northern Trust1,264,8850 00For
Hillsdale Investment Management Inc.1,154,0780 00For
Pacer Funds Trust1,133,7280 00For
Bridge Builder Trust906,7820 00For
Invesco826,3080 00For
Dimensional781,4020 00For
Victory Capital744,5710 00For
Goldman Sachs0726,228 00Against
Voya686,6350 00For

Showing the 25 largest of 196 asset managers. See all 196 in the interactive database.

2. Election of Directors. To elect eight director nominees numbered 01 through 08 to serve for a one-year term extending until the 2027 annual meeting of stockholders and their successors are duly elected and qualified: Alexander Denner, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 7 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 104,323,731WITHHELD: 5,313,973

Ironwood Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Alexander Denner, Ph.D.”): 104,323,731 for, 5,313,973 withheld, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 164,613,406 outstanding shares: 63% for, 3% withheld (67% of the company cast a for/withheld vote).

The 66 asset managers below cast 100% of the shares they voted on this item FOR (42,124,002 for, 0 against).

FOR 99.4%
FOR: 42,124,002 (99.4%)ABSTAIN: 241,470 (0.6%)
Largest asset managers voting on “Election of Directors. To elect eight director nominees numbered 01 through 08 to serve for a one-year term ex” at Ironwood Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard12,264,4660 20,2580For
Fidelity4,985,2510 00For
Charles Schwab4,756,1630 00For
State Street4,502,2890 5,7940For
BlackRock4,269,2510 00For
Federated Hermes2,251,1590 00For
Pacer Funds Trust1,133,7280 00For
Bridge Builder Trust906,7820 00For
SEI686,8470 00For
Dimensional601,4650 00For
Northern Lights Fund Trust IV529,7790 00For
Equitable375,7610 00For
BRIDGEWAY FUNDS INC365,4930 00For
Invesco342,5410 00For
AQR302,4500 00For
Voya276,9300 00For
QUANTITATIVE MASTER SERIES LLC272,1890 00For
TARGET PORTFOLIO TRUST230,3000 00For
Putnam205,7340 00For
Lincoln Financial204,5930 00For
TIAA195,7370 00For
ETF Series Solutions00 184,3370Abstain
Franklin Templeton184,0080 00For
Nationwide175,0080 00For
GuideStone164,4570 00For

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

3. Election of Directors. To elect eight director nominees numbered 01 through 08 to serve for a one-year term extending until the 2027 annual meeting of stockholders and their successors are duly elected and qualified: Catherine Moukheibir

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 106,410,985WITHHELD: 3,226,719

Ironwood Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Catherine Moukheibir”): 106,410,985 for, 3,226,719 withheld, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 164,613,406 outstanding shares: 65% for, 2% withheld (67% of the company cast a for/withheld vote).

The 66 asset managers below cast 100% of the shares they voted on this item FOR (42,144,471 for, 0 against).

FOR 99.4%
FOR: 42,144,471 (99.5%)ABSTAIN: 221,001 (0.5%)
Largest asset managers voting on “Election of Directors. To elect eight director nominees numbered 01 through 08 to serve for a one-year term ex” at Ironwood Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard12,271,1620 13,5620For
Fidelity4,985,2510 00For
Charles Schwab4,756,1630 00For
State Street4,502,2890 5,7940For
BlackRock4,269,2510 00For
Federated Hermes2,251,1590 00For
Pacer Funds Trust1,133,7280 00For
Bridge Builder Trust906,7820 00For
SEI686,8470 00For
Dimensional601,4650 00For
Northern Lights Fund Trust IV529,7790 00For
Equitable375,7610 00For
BRIDGEWAY FUNDS INC365,4930 00For
Invesco342,5410 00For
AQR302,4500 00For
Voya276,9300 00For
QUANTITATIVE MASTER SERIES LLC272,1890 00For
TARGET PORTFOLIO TRUST230,3000 00For
Putnam205,7340 00For
Lincoln Financial204,5930 00For
TIAA195,7370 00For
ETF Series Solutions00 184,3370Abstain
Franklin Templeton184,0080 00For
Nationwide175,0080 00For
GuideStone164,4570 00For

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

4. Election of Directors. To elect eight director nominees numbered 01 through 08 to serve for a one-year term extending until the 2027 annual meeting of stockholders and their successors are duly elected and qualified: Jay Shepard

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 107,209,046WITHHELD: 2,428,658

Ironwood Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Jay Shepard”): 107,209,046 for, 2,428,658 withheld, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 164,613,406 outstanding shares: 65% for, 1% withheld (67% of the company cast a for/withheld vote).

The 66 asset managers below cast 100% of the shares they voted on this item FOR (42,144,474 for, 0 against).

FOR 99.4%
FOR: 42,144,474 (99.5%)ABSTAIN: 220,998 (0.5%)
Largest asset managers voting on “Election of Directors. To elect eight director nominees numbered 01 through 08 to serve for a one-year term ex” at Ironwood Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard12,271,1650 13,5590For
Fidelity4,985,2510 00For
Charles Schwab4,756,1630 00For
State Street4,502,2890 5,7940For
BlackRock4,269,2510 00For
Federated Hermes2,251,1590 00For
Pacer Funds Trust1,133,7280 00For
Bridge Builder Trust906,7820 00For
SEI686,8470 00For
Dimensional601,4650 00For
Northern Lights Fund Trust IV529,7790 00For
Equitable375,7610 00For
BRIDGEWAY FUNDS INC365,4930 00For
Invesco342,5410 00For
AQR302,4500 00For
Voya276,9300 00For
QUANTITATIVE MASTER SERIES LLC272,1890 00For
TARGET PORTFOLIO TRUST230,3000 00For
Putnam205,7340 00For
Lincoln Financial204,5930 00For
TIAA195,7370 00For
ETF Series Solutions00 184,3370Abstain
Franklin Templeton184,0080 00For
Nationwide175,0080 00For
GuideStone164,4570 00For

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

5. Election of Directors. To elect eight director nominees numbered 01 through 08 to serve for a one-year term extending until the 2027 annual meeting of stockholders and their successors are duly elected and qualified: Jon Duane

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 105,956,515WITHHELD: 3,681,189

Ironwood Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Jon Duane”): 105,956,515 for, 3,681,189 withheld, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 164,613,406 outstanding shares: 64% for, 2% withheld (67% of the company cast a for/withheld vote).

The 66 asset managers below cast 100% of the shares they voted on this item FOR (42,130,698 for, 0 against).

FOR 99.4%
FOR: 42,130,698 (99.4%)ABSTAIN: 234,774 (0.6%)
Largest asset managers voting on “Election of Directors. To elect eight director nominees numbered 01 through 08 to serve for a one-year term ex” at Ironwood Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard12,271,1620 13,5620For
Fidelity4,985,2510 00For
Charles Schwab4,756,1630 00For
State Street4,502,2890 5,7940For
BlackRock4,269,2510 00For
Federated Hermes2,251,1590 00For
Pacer Funds Trust1,133,7280 00For
Bridge Builder Trust906,7820 00For
SEI686,8470 00For
Dimensional601,4650 00For
Northern Lights Fund Trust IV529,7790 00For
Equitable375,7610 00For
BRIDGEWAY FUNDS INC365,4930 00For
Invesco342,5410 00For
AQR302,4500 00For
Voya276,9300 00For
QUANTITATIVE MASTER SERIES LLC272,1890 00For
TARGET PORTFOLIO TRUST230,3000 00For
Putnam205,7340 00For
Lincoln Financial204,5930 00For
TIAA195,7370 00For
ETF Series Solutions00 184,3370Abstain
Franklin Templeton184,0080 00For
Nationwide175,0080 00For
GuideStone164,4570 00For

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

6. Election of Directors. To elect eight director nominees numbered 01 through 08 to serve for a one-year term extending until the 2027 annual meeting of stockholders and their successors are duly elected and qualified: Julie McHugh

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 7 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 104,403,033WITHHELD: 5,234,671

Ironwood Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Julie McHugh”): 104,403,033 for, 5,234,671 withheld, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 164,613,406 outstanding shares: 63% for, 3% withheld (67% of the company cast a for/withheld vote).

The 66 asset managers below cast 100% of the shares they voted on this item FOR (42,123,823 for, 0 against).

FOR 99.4%
FOR: 42,123,823 (99.4%)ABSTAIN: 241,649 (0.6%)
Largest asset managers voting on “Election of Directors. To elect eight director nominees numbered 01 through 08 to serve for a one-year term ex” at Ironwood Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard12,264,4670 20,2570For
Fidelity4,985,2510 00For
Charles Schwab4,756,1630 00For
State Street4,502,1100 5,9730For
BlackRock4,269,2510 00For
Federated Hermes2,251,1590 00For
Pacer Funds Trust1,133,7280 00For
Bridge Builder Trust906,7820 00For
SEI686,8470 00For
Dimensional601,4650 00For
Northern Lights Fund Trust IV529,7790 00For
Equitable375,7610 00For
BRIDGEWAY FUNDS INC365,4930 00For
Invesco342,5410 00For
AQR302,4500 00For
Voya276,9300 00For
QUANTITATIVE MASTER SERIES LLC272,1890 00For
TARGET PORTFOLIO TRUST230,3000 00For
Putnam205,7340 00For
Lincoln Financial204,5930 00For
TIAA195,7370 00For
ETF Series Solutions00 184,3370Abstain
Franklin Templeton184,0080 00For
Nationwide175,0080 00For
GuideStone164,4570 00For

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

7. Election of Directors. To elect eight director nominees numbered 01 through 08 to serve for a one-year term extending until the 2027 annual meeting of stockholders and their successors are duly elected and qualified: Mark Currie, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 7 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 107,222,711WITHHELD: 2,414,993

Ironwood Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Mark Currie, Ph.D.”): 107,222,711 for, 2,414,993 withheld, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 164,613,406 outstanding shares: 65% for, 1% withheld (67% of the company cast a for/withheld vote).

The 66 asset managers below cast 100% of the shares they voted on this item FOR (42,144,474 for, 0 against).

FOR 99.4%
FOR: 42,144,474 (99.5%)ABSTAIN: 220,998 (0.5%)
Largest asset managers voting on “Election of Directors. To elect eight director nominees numbered 01 through 08 to serve for a one-year term ex” at Ironwood Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard12,271,1650 13,5590For
Fidelity4,985,2510 00For
Charles Schwab4,756,1630 00For
State Street4,502,2890 5,7940For
BlackRock4,269,2510 00For
Federated Hermes2,251,1590 00For
Pacer Funds Trust1,133,7280 00For
Bridge Builder Trust906,7820 00For
SEI686,8470 00For
Dimensional601,4650 00For
Northern Lights Fund Trust IV529,7790 00For
Equitable375,7610 00For
BRIDGEWAY FUNDS INC365,4930 00For
Invesco342,5410 00For
AQR302,4500 00For
Voya276,9300 00For
QUANTITATIVE MASTER SERIES LLC272,1890 00For
TARGET PORTFOLIO TRUST230,3000 00For
Putnam205,7340 00For
Lincoln Financial204,5930 00For
TIAA195,7370 00For
ETF Series Solutions00 184,3370Abstain
Franklin Templeton184,0080 00For
Nationwide175,0080 00For
GuideStone164,4570 00For

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

8. Election of Directors. To elect eight director nominees numbered 01 through 08 to serve for a one-year term extending until the 2027 annual meeting of stockholders and their successors are duly elected and qualified: Marla Kessler

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 107,142,336WITHHELD: 2,495,368

Ironwood Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Marla Kessler”): 107,142,336 for, 2,495,368 withheld, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 164,613,406 outstanding shares: 65% for, 2% withheld (67% of the company cast a for/withheld vote).

The 66 asset managers below cast 100% of the shares they voted on this item FOR (42,144,474 for, 0 against).

FOR 99.4%
FOR: 42,144,474 (99.5%)ABSTAIN: 220,998 (0.5%)
Largest asset managers voting on “Election of Directors. To elect eight director nominees numbered 01 through 08 to serve for a one-year term ex” at Ironwood Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard12,271,1650 13,5590For
Fidelity4,985,2510 00For
Charles Schwab4,756,1630 00For
State Street4,502,2890 5,7940For
BlackRock4,269,2510 00For
Federated Hermes2,251,1590 00For
Pacer Funds Trust1,133,7280 00For
Bridge Builder Trust906,7820 00For
SEI686,8470 00For
Dimensional601,4650 00For
Northern Lights Fund Trust IV529,7790 00For
Equitable375,7610 00For
BRIDGEWAY FUNDS INC365,4930 00For
Invesco342,5410 00For
AQR302,4500 00For
Voya276,9300 00For
QUANTITATIVE MASTER SERIES LLC272,1890 00For
TARGET PORTFOLIO TRUST230,3000 00For
Putnam205,7340 00For
Lincoln Financial204,5930 00For
TIAA195,7370 00For
ETF Series Solutions00 184,3370Abstain
Franklin Templeton184,0080 00For
Nationwide175,0080 00For
GuideStone164,4570 00For

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

9. Election of Directors. To elect eight director nominees numbered 01 through 08 to serve for a one-year term extending until the 2027 annual meeting of stockholders and their successors are duly elected and qualified: Thomas McCourt

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 7 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 107,152,086WITHHELD: 2,485,618

Ironwood Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Thomas McCourt”): 107,152,086 for, 2,485,618 withheld, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 164,613,406 outstanding shares: 65% for, 2% withheld (67% of the company cast a for/withheld vote).

The 66 asset managers below cast 100% of the shares they voted on this item FOR (42,144,474 for, 0 against).

FOR 99.4%
FOR: 42,144,474 (99.5%)ABSTAIN: 220,998 (0.5%)
Largest asset managers voting on “Election of Directors. To elect eight director nominees numbered 01 through 08 to serve for a one-year term ex” at Ironwood Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard12,271,1650 13,5590For
Fidelity4,985,2510 00For
Charles Schwab4,756,1630 00For
State Street4,502,2890 5,7940For
BlackRock4,269,2510 00For
Federated Hermes2,251,1590 00For
Pacer Funds Trust1,133,7280 00For
Bridge Builder Trust906,7820 00For
SEI686,8470 00For
Dimensional601,4650 00For
Northern Lights Fund Trust IV529,7790 00For
Equitable375,7610 00For
BRIDGEWAY FUNDS INC365,4930 00For
Invesco342,5410 00For
AQR302,4500 00For
Voya276,9300 00For
QUANTITATIVE MASTER SERIES LLC272,1890 00For
TARGET PORTFOLIO TRUST230,3000 00For
Putnam205,7340 00For
Lincoln Financial204,5930 00For
TIAA195,7370 00For
ETF Series Solutions00 184,3370Abstain
Franklin Templeton184,0080 00For
Nationwide175,0080 00For
GuideStone164,4570 00For

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

10. RATIFICATION OF THE SELECTION OF KPMG LLP AS IRONWOOD PHARMACEUTICALS, INC.'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR 2026.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 121,957,895AGAINST: 2,783,154

Ironwood Pharmaceuticals, Inc.’s own tally for this item (“Proposal 4: The stockholders ratified the selection of KPMG LLP as the Company's independent registered public accounting firm for 2026, based on the following votes:”): 121,957,895 for, 2,783,154 against, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 164,613,406 outstanding shares: 74% for, 2% against (76% of the company cast a for/against vote).

The 66 asset managers below cast 99.1% of the shares they voted on this item FOR (41,981,583 for, 367,343 against).

FOR 99.0%
FOR: 41,981,583 (99.1%)AGAINST: 367,343 (0.9%)ABSTAIN: 16,546 (0.0%)
Largest asset managers voting on “RATIFICATION OF THE SELECTION OF KPMG LLP AS IRONWOOD PHARMACEUTICALS, INC.'S INDEPENDENT REGISTERED PUBLIC AC” at Ironwood Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard12,284,7159 00For
Fidelity4,985,2510 00For
Charles Schwab4,756,1630 00For
State Street4,506,2421,841 00For
BlackRock4,269,2510 00For
Federated Hermes2,251,1590 00For
Pacer Funds Trust1,133,7280 00For
Bridge Builder Trust906,7820 00For
SEI686,8470 00For
Dimensional601,4650 00For
Northern Lights Fund Trust IV529,7790 00For
Equitable375,7610 00For
BRIDGEWAY FUNDS INC0365,493 00Against
Invesco342,5410 00For
AQR302,4500 00For
Voya276,9300 00For
QUANTITATIVE MASTER SERIES LLC272,1890 00For
TARGET PORTFOLIO TRUST230,3000 00For
Putnam205,7340 00For
Lincoln Financial204,5930 00For
TIAA195,7370 00For
ETF Series Solutions184,3370 00For
Franklin Templeton184,0080 00For
Nationwide175,0080 00For
GuideStone164,4570 00For

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

11. APPROVAL OF AN AMENDMENT TO IRONWOOD PHARMACEUTICALS, INC. AMENDED AND RESTATED 2019 EQUITY INCENTIVE PLAN TO INCREASE THE NUMBER OF SHARES AVAILABLE FOR ISSUANCE THEREUNDER BY 10,000,000 SHARES.

COMPENSATIONMajority of the votes cast: yes

95% Majority: yes · of votes cast

FOR 95%
FOR: 104,066,785AGAINST: 5,404,112

Ironwood Pharmaceuticals, Inc.’s own tally for this item (“Proposal 3: The stockholders approved the Plan Amendment, based on the following votes:”): 104,066,785 for, 5,404,112 against, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 164,613,406 outstanding shares: 63% for, 3% against (67% of the company cast a for/against vote).

The 64 asset managers below cast 99.5% of the shares they voted on this item FOR (42,033,763 for, 209,858 against).

FOR 99.4%
FOR: 42,033,763 (99.5%)AGAINST: 209,858 (0.5%)ABSTAIN: 16,546 (0.0%)
Largest asset managers voting on “APPROVAL OF AN AMENDMENT TO IRONWOOD PHARMACEUTICALS, INC. AMENDED AND RESTATED 2019 EQUITY INCENTIVE PLAN TO ” at Ironwood Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard12,284,70915 00For
Fidelity4,985,2510 00For
Charles Schwab4,756,1630 00For
State Street4,507,903180 00For
BlackRock4,269,2510 00For
Federated Hermes2,251,1590 00For
Pacer Funds Trust1,133,7280 00For
Bridge Builder Trust906,7820 00For
SEI686,8470 00For
Dimensional601,4650 00For
Northern Lights Fund Trust IV529,7790 00For
Equitable375,7610 00For
BRIDGEWAY FUNDS INC365,4930 00For
Invesco342,5410 00For
AQR302,4500 00For
Voya276,9300 00For
QUANTITATIVE MASTER SERIES LLC272,1890 00For
TARGET PORTFOLIO TRUST230,3000 00For
Putnam0205,734 00Against
Lincoln Financial204,5930 00For
TIAA195,7370 00For
ETF Series Solutions184,3370 00For
Franklin Templeton184,0080 00For
Nationwide175,0080 00For
GuideStone164,4570 00For

Showing the 25 largest of 64 asset managers. See all 64 in the interactive database.

12. Amend Omnibus Stock Plan

COMPENSATIONMajority of the votes cast: yes

95% Majority: yes · of votes cast

FOR 95%
FOR: 104,066,785AGAINST: 5,404,112

Ironwood Pharmaceuticals, Inc.’s own tally for this item (“Proposal 3: The stockholders approved the Plan Amendment, based on the following votes:”): 104,066,785 for, 5,404,112 against, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 164,613,406 outstanding shares: 63% for, 3% against (67% of the company cast a for/against vote).

The 2 asset managers below cast 100% of the shares they voted on this item FOR (105,305 for, 0 against).

FOR 100%
FOR: 105,305 (100.0%)
Largest asset managers voting on “Amend Omnibus Stock Plan” at Ironwood Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
CLEARWATER INVESTMENT TRUST70,7630 00For
FORUM FUNDS II34,5420 00For

Largest Ironwood Pharmaceuticals, Inc. shareholders voting in 2025-2026

Ranked by the number of Ironwood Pharmaceuticals, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 164,613,406 shares outstanding at the time of that meeting.

Top Ironwood Pharmaceuticals, Inc. shareholders by shares voted, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 8.46%
2BlackRock 5.80%
3Charles Schwab 5.78%
4State Street 4.49%
5Fidelity 3.52%
6AQR 3.37%
7Federated Hermes 3.36%
8Renaissance 3.35%
9GEODE CAPITAL MANAGEMENT, LLC 2.78%
10ACADIAN ASSET MANAGEMENT LLC 2.66%

Reported Ironwood Pharmaceuticals, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Ironwood Pharmaceuticals, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder % outstanding Disclosure
Vanguard Group 9.69% 13F
Armistice Capital, LLC 8.46% 13G
BlackRock 8.12% 13F
BANK OF AMERICA CORP /DE/ 6.05% 13G
Alexander Denner, Ph.D. 5.74% DEF14A
Sarissa Capital Management LP 5.58% DEF14A
Renaissance Technologies 4.90% 13F
State Street 4.53% 13F
Two Sigma 3.55% 13F
Charles Schwab 2.88% 13F

Percentages above are of 164,613,406 shares outstanding, as reported by Ironwood Pharmaceuticals, Inc. on its Form 10-Q dated 2026-04-30 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Ironwood Pharmaceuticals, Inc.’s 10-Q dated 2026-04-30. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Ironwood Pharmaceuticals, Inc.'s shareholder meeting held 2026-06-16, in the 2025-2026 proxy season, 196 asset managers reported how they voted in their SEC Form N-PX filings, covering 2,418 separate fund positions. Their filings are grouped here into 12 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Approval, by non-binding advisory vote, of the compensation paid to the named executive… — FOR was 95% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Ironwood Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-18.

Ironwood Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).